Arcutis Biotherapeutics Inc (NAS:ARQT)
$ 8.41 0.06 (0.72%) Market Cap: 983.05 Mil Enterprise Value: 821.17 Mil PE Ratio: 0 PB Ratio: 5.22 GF Score: 36/100

Arcutis Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 12:00PM GMT
Release Date Price: $20.44 (-5.06%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Joining us. My name is Vikram Purohit. I'm one of the biotech analysts with Morgan Stanley Research. This is the fireside chat with Arcutis Biotherapeutics. Very happy to have with me CEO, Frank Watanabe. Frank, thanks for joining us.

Todd Franklin Watanabe
Arcutis Biotherapeutics, Inc. - President, CEO & Director

Thanks for being having me.

Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Of course. Before we get started, I need to read a brief disclosure. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. (Operator Instructions)

Questions & Answers

Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

With that, let's get started. We have around 30 minutes. Frank, before we jump into any

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot